Pentapeptide-18
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A synthetic pentapeptide in wrinkle serums that mimics enkephalins to relax facial muscles, marketed as a Botox alternative. Evidence is limited to small, open-label, manufacturer-funded trials with modest results, not blinded studies; other benefits are speculative, from lab or computational work. No serious adverse effects are reported, but long-term safety data are scarce; it remains unapproved, sold as a cosmetic ingredient, not a research peptide.
Read Full recordStudied uses & evidence
Studied uses(6)
Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)
SpeculativePublished human studies exist, including a 20-person uncontrolled study in 2014; rigorous evidence isolating the peptide's effect remains limited.
Synergistic wrinkle reduction when combined with Argireline (Acetyl Hexapeptide-8)
SpeculativeMarketing rationale only; no published study has tested the combination in humans or cells.
Non-invasive Botox-like muscle relaxation without loss of facial expressivity
SpeculativeMechanism-based only; no human EMG studies or comparisons with botulinum toxin exist.
Evidence limits
- Evidence Level
- Moderate
The clinical evidence for Pentapeptide-18 is consistent but limited in scope and rigor. The manufacturer's 2005 in-vivo studies (Lipotec) across three arms (14-15 volunteers each, 28 days) demonstrated 11.64% wrinkle reduction for Leuphasyl alone and 24.62% for the combination with Argireline. Dragomirescu et al. (2014) independently confirmed efficacy at 2% concentration in 20 volunteers over 2 months (34.7% frontal, 28.4% periorbital wrinkle reduction) and established a dose-response threshold. Two 2024 studies by Pawlowska et al. showed improved delivery via nanoparticle formulations. Park et al. (2020) added anti-melanogenic evidence using D-tyrosine derivatives. All studies report excellent safety with no adverse effects. However, there are no large RCTs, no long-term safety data beyond 2 months, and most core efficacy claims rest on manufacturer-sponsored data. The evidence is sufficient for cosmetic claims but far below pharmaceutical standards.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
No known serious adverse effects
LowPotential skin sensitivity in hypersensitive individuals
LowLimited long-term safety data
ModerateTheoretical opioid receptor activation
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.